Cybin Inc announced a groundbreaking funding agreement with High Trail Capital, securing up to $500 million to support its late-stage psychedelic drug programs CYB003 and CYB004—marking the largest financing of its kind in the sector. 🔹 Initial $50M raised via 5.5% convertible

Ainos Expands AI-Powered SmellTech Across Key Industrial Verticals 🔹 ASE Technology to deploy up to 15,000 AI Nose units in semiconductor cleanrooms 🔹 Kenmec licenses AI Nose for smart factories, logistics, and automation across Asia 🔹 Solomon Technology signs 5-year deal to

Compass Pathways posts Phase 3 data on psilocybin treatment for TRD 🔹 COMP360 met its primary endpoint with a statistically significant -3.6 MADRS score difference vs. placebo (p<0.001) in its Phase 3 COMP005 trial 🔹 Safety profile was favorable, with no new or unexpected

New Episode: WTR Small-Cap Spotlight featuring Cybin (NYSE American: CYBN) CybinInc CEO Doug Drysdale joins WTR’s Tim Gerdeman and Robert Sassoon to break down the company’s innovative financing strategy and share insights on how lead candidate CYB003 may stand apart in the

Check out Robert Sassoon's recap from his latest podcast with Doug Drysdale, CEO of CybinInc (NYSE:CYBN) dsicussing company’s recent financing activity and differences in data between Cybin’s lead depression drug candidate psilocin-based CYB003 and other aspiring late-stage

On the latest WTR Healthcare Spotlight podcast, Tim Gerdeman and Robert Sassoon were joined by Lisata Therapeutics, Inc. (NASDAQ: LSTA) CEO David J. Mazzo, Ph.D., PhD, and CMO Kristen K. Buck MD, to discuss Certepetide—Lisata’s novel tumor-penetrating therapy—and encouraging preliminary Phase

Cybin Inc expands its Phase 3 program for CYB003 with UK regulatory approval. 🔹 UK MHRA approves EMBRACE, a larger, multinational follow-up to the APPROACH study for major depressive disorder (MDD) 🔹 EMBRACE will enroll 330 patients across 60 sites in the US, Europe, and

Check out Robert Sassoon's recap following his latest podcast with Lisata Therapeutics, Inc. (NASDAQ:LSTA) CEO David J. Mazzo, Ph.D., PhD and Chief Medical Officer and Head of R&D Kristen K. Buck MD to talk about, Certepetide, the company’s novel solid tumor targeting and

New Episode Alert: WTR Small-Cap Spotlight WTR's Tim Gerdeman & Robert Sassoon joined by Jack Lu, Director of Corporate Development at Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMD), to explore the company’s innovative AI Nose smell digitization platform. 🔹 Strategic partnerships expanding use

Lisata's leadership team recently discussed its novel tumor-penetrating therapy, certepetide, and the preliminary Ph 2b results in mPDAC on Water Tower Research LLC podcast. Key topics: lead program insights, partnerships, & what’s next Listen: pod.link/1693448305 #LisataTherapeutics

Read Robert Sassoon's recap and transcript from his recent fireside chat with Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMD) Director of Corporate Development, Jack Lu, discussing the company’s pioneering smell digitization AI technology platform, AI Nose, diversification of the platform’s

CYBN: CYB003 vs. GH001 New Data Alert: GH Research (NASDAQ: GHRS) released final 6-month data from its Phase 2b OLE study of GH001 for treatment-resistant depression (TRD), showing a 73% remission rate among completers. Including early dropouts, remission is still a solid ~57%.

Ainos' VELDONA Advances with Taiwan FDA Approval Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMD) announces Taiwan FDA approval to start a key clinical study for its low-dose oral interferon-alpha drug candidate, VELDONA, targeting primary Sjögren’s syndrome (pSS). 🔹 Major Milestone: Approval for

New Coverage Alert: Tian Ruixiang Holdings (NASDAQ: TIRX) WTR has initiated coverage on TIRX, a company blending AI-powered risk analytics with traditional brokerage to tap China’s $280B health insurance market opportunity. 🔹 Leveraging Ucare’s 90%+ margin SaaS platform with

Cybin Inc secures EU green light for EMBRACE Phase 3 trial ✅ — advancing its CYB003 program for major depressive disorder. 🔹 Irish Medicines Board approves CTA, enabling trial launch in Ireland, Poland & Greece 🔹 EMBRACE to enroll 330 patients across 60 sites in the US,

Please join Robert Sassoon for a conversation with Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMD) Director of Corporate Development Jack Lu on Wednesday, August 20, 2025, at 11:00 am ET. Register Below! us06web.zoom.us/webinar/regist… $AIMD #Ainos #AI #AINose #AISmell #SmellTech #SmallCap #Stocks

New WTR Healthcare Happenings Podcast! Envoy Medical CEO Brent Lucas joins Tim Gerdeman & Robert Sassoon to discuss how the company is disrupting the hearing solutions market — one that has long lacked transformative innovation. 🔹 Hearing loss is the 3rd most common chronic

Catch Robert Sassoon's recap from his recent podcast with Brent Lucas, CEO of Envoy Medical (NASDAQ: COCH), an innovative hearing technology company and the sole US-domiciled cochlear implant company. We discussed the segment of the hearing loss market that Envoy is addressing

Ainos, Inc. (NASDAQ: AIMD) is now being covered under our Technology platform, reflecting its pivot from biotech roots to a leading AI innovator with its AI Nose digital SmellTech platform. 🔹 Strategic focus shifting to large-scale commercialization of AI Nose in 2026 🔹 13

Enlivex Therapeutics (Nasdaq: ENLV) announced positive topline Phase I/II data from its Allocetra™ trial in patients with moderate-to-severe knee osteoarthritis. 🔹 24% reduction in knee pain & 26% improvement in function in overall mITT population 🔹 Age-related primary OA